BioSpace News Archive

Aditxt, Inc. today announced that it has closed its previously announced private placement for the purchase and sale of an aggregate of 1,237,114 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $4.85 per share.

Biocare Medical, a leader in fully open automated instrumentation, announces a collaboration with Molecular Instruments® (MI), the inventor of the HCR™ Imaging technology.

Standard BioTools Inc. announced that it has completed its merger with SomaLogic, creating a leading provider of differentiated multi-omics tools for research.

Metrodora Institute, a leading multispecialty healthcare institute, announces the hiring of Rohit Gupta, a nationally recognized scientist, biobank, and data expert, as its new Chief Scientific Officer and Head of R&D.

Cassava Sciences, Inc. announced the completion of a previously announced distribution of warrants to its shareholders.

Tiziana Life Sciences Ltd. today announced that its Chief Operating Officer and Chief Medical Officer, Matthew Davis, MD, RPh, will present at Biotech Showcase, San Francisco, January 8-10, 2024.

Novartis announced today that it has received approval from the US Food and Drug Administration (FDA) for commercial manufacturing of PluvictoTM (INN: lutetium (177Lu) vipivotide tetraxetan / USAN: lutetium Lu 177 vipivotide tetraxetan) at its new large-scale, state-of-the-art radioligand therapy (RLT) manufacturing facility in Indianapolis, Indiana, United States.

The U.S. Food and Drug Administration authorized Florida’s Agency for Health Care Administration’s drug importation program under section 804 of the Federal Food, Drug, and Cosmetic Act.

AOBiome Therapeutics Inc. (“AOB”) announced today that is has entered into an exclusive license and development agreement with Maruho Co., Ltd., to develop and commercialize AOB’s topical biologic B244 (currently preparing for global Phase 3 clinical trials), a therapeutic treatment for dermatological indications including Atopic Dermatitis, for both appearance and pruritus (itch).

Sail Biomedicines, Inc. today provided an update on its research funded by the Cystic Fibrosis Foundation (CF Foundation), with preclinical data that suggest that Sail’s Endless RNA™ (eRNA™) may offer the potential to treat the 10%-15% of people with CF for whom existing treatments are not an option.